| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 05/17/2001 | WO2001034124A2 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system |
| 05/17/2001 | WO2001022955A3 Novel combination of loteprednol and antihistamines |
| 05/17/2001 | WO2001014360A3 Benzopyrans and benzothiopyrans as rar selective retinoid agonists |
| 05/17/2001 | WO2001014358A3 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
| 05/17/2001 | WO2001007471A9 Cell cycle and proliferation proteins |
| 05/17/2001 | WO2001001973A8 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/17/2001 | WO2000071108A3 Methods for treatment of asthma using s-oxybutynin |
| 05/17/2001 | WO1999044620A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/17/2001 | DE19954707A1 Imidazolverbindungen als Phosphodiesterase VII-Hemmer Imidazole compounds as phosphodiesterase VII inhibitor |
| 05/17/2001 | DE19953899A1 Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Carboxamide-substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 05/17/2001 | DE19953829A1 New nasal spray containing vitamin C and extracts of Bulpeurum Scorzonerifolium Willd, Radix lastidis Indigotica and Folium lastidis for treating colds, fever and influenza |
| 05/17/2001 | DE19953625A1 Verwendung von 5HT-1A Serotonin Rezeptor Agonisten zur Behandlung von genetischen oder funktionellen Atemrhythmusstörungen Use of 5-HT 1A serotonin receptor agonist for the treatment of genetic or functional respiratory arrhythmia |
| 05/17/2001 | CA2390919A1 Nose drop containing condensed pyridazine |
| 05/17/2001 | CA2390496A1 Polycycloalkylpurines as adenosine receptor antagonists |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2389724A1 28 human secreted proteins |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2388914A1 15 human secreted proteins |
| 05/17/2001 | CA2388729A1 Imidazopyridine derivatives as phosphodiesterase vii inhibitors |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387964A1 22 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2387089A1 Interferon gamma for the treatment of asthma |
| 05/17/2001 | CA2361139A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
| 05/16/2001 | EP1098886A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors |
| 05/16/2001 | EP1098884A1 Il-8 receptor antagonists |
| 05/16/2001 | EP1098870A2 Nitric esters and nitrate salts of specific drugs |
| 05/16/2001 | EP1098663A1 Slow release formulations comprising anionic polysaccharide |
| 05/16/2001 | EP1098654A1 Antilipemic composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP1098645A1 Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ards) and infant respiratory distress syndrome (irds) |
| 05/16/2001 | EP1098640A1 Anti-ulcer composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
| 05/16/2001 | EP0859766B1 Chiral methyl phenyl oxazolidinones |
| 05/16/2001 | CN1295579A Therapeutic uses of keratinocyte growth factor-2 |
| 05/16/2001 | CN1295571A PDE IV inhibiting pyridine derivatives |
| 05/16/2001 | CN1295563A 2-arylethyl-(piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists |
| 05/16/2001 | CN1295479A Beta 2-adrenergic receptor agonist |
| 05/16/2001 | CN1295471A Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders |
| 05/16/2001 | CN1295065A Phenyl heterocyclic compound used as epoxy enzyme -2 inhibitor |
| 05/16/2001 | CN1294923A Nose drop of Fructus Psoraleae and its production process |
| 05/16/2001 | CN1294919A Cough treating medicine and its preparation |
| 05/16/2001 | CN1294911A Substituted nitrobenzene derivative for medicine and other use |
| 05/16/2001 | CN1065766C Chiense medicine-nasal spray for treatment of rhinitis and its prep. |
| 05/15/2001 | US6232321 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 05/15/2001 | US6232305 Substituted amino bicyclic-β-lactam penam and cepham derivatives as cysteine protease inhibitors |
| 05/15/2001 | US6232097 Nucleotide sequences coding enzymatic polypeptide; prevent bacterial infection; wound healing agents; for vaccine development |
| 05/15/2001 | US6232077 Genetic engineering and expression; cancer diagnosis |
| 05/15/2001 | US6232064 Fibrosis and atherosclerosis determination |
| 05/15/2001 | CA2180011C Botulinum toxins for treating sweating |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001032925A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | WO2001032910A2 27 human secreted proteins |
| 05/10/2001 | WO2001032898A2 Recombinant sendai virus vector for introducing exogenous genes to airway epithelia |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032714A1 Recombinant fusion molecules |
| 05/10/2001 | WO2001032709A2 Polypeptides with non-natural primary signalling motifs |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032656A1 Polymorphic form of a tachykinin receptor antagonist |
| 05/10/2001 | WO2001032649A1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032611A1 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032202A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | WO2001032175A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032166A1 NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032163A1 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032127A2 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | WO2001021804B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2000073276A3 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | WO2000016745A3 Micronised pharmaceutical compositions |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953024A1 Isoxazolderivate als Phosphodiesterase VII-Hemmer Isoxazole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389655A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |